Nicholas Mai

Oct 17, 2024 | nature.com | Nicholas Mai |Pedram Razavi |Anton Safonov |Chau Dang |Larry Norton |Mark E. Robson | +1 more

AbstractAfter disease progression on endocrine therapy (ET) plus a CDK4/6 inhibitor, there is no standardized sequence for subsequent treatment lines for estrogen receptor positive (ER+) metastatic breast cancer (MBC). CDK4/6i retrial as a treatment strategy is commonplace in modern clinical practice; however, the available prospective data investigating this strategy have had inconclusive results.

Jul 27, 2024 | nature.com | Nicholas Mai |Jie-Fu Chen |Sarat Chandarlapaty

AbstractSimultaneous presentation of two separate primary breast cancers of differing histology at initial diagnosis is an uncommon phenomenon; it is even rarer to find these pathologically distinct populations within the same biopsy.